The cellular cancer resistance of the SR/CR mouse

APMIS

Volumn 120, Issue 12, 2012, Pages 974-987

  Koch, Janne ^a,b   Hau, Jann ^a   Jensen, Henrik E ^b   Nielsen, Claus H ^c   Rieneck, Klaus ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

Cancer resistance; Macrophages; Natural killer cells; Polymorphonuclear granulocytes; S180 sarcoma cells

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER RESISTANCE; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; LEUKOCYTE; MACROPHAGE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PERITONEAL CAVITY; PERITONEAL FLUID; PERITONEUM EXUDATE; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; SR/CR MOUSE; UPREGULATION;

ANIMALS; ASCITIC FLUID; B-LYMPHOCYTES; CELL LINE, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GRANULOCYTES; IMMUNITY, INNATE; INTERLEUKIN-10; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PERITONEAL CAVITY; SARCOMA 180; SPLEEN;

EID: 84869080772     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02925.x     Document Type: Article

References (24)

1. Egorov OS, Liu Y, Sargent EE, Drizlikh GI, Egorov IK Screening mouse mutations for resistance to cancer metastasis. Immunogenetics 1991;36:219-23.
2. Cui Z, Willingham MC, Hicks AM, et al. Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. PNAS 2003;100:6682-7.
3. Alfaro G, Lomeli C, Ocadiz R, et al. Immunologic and genetic characterization of S180, a cell line of murine origin capable of growing in different inbred strains of mice. Vet Immunol Immunopathol 1992;30:385-98.
4. Riedlinger G, Adams JM, Stehle JR Jr, et al. The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. BMC Cancer 2010;10:179.
5. Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. PNAS 2006;103:7753-8.
6. Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, Cui Z Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immunity 2006;6:11-20.
7. Koch J, Boschnian A, Hau J, Rieneck K Frequency of the cancer resistant phenotype in SR/CR mice and the effect of litter seriation. In vivo 2008;22:565-9.
8. Borregaard N Neutrophils, from Marrow to Microbes. Immunity 2010;33:657-70.
9. Scapini P, Lapinet-Vera JA, Gasperini S, Bazzoni F, Cassatella MA The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203.
10. Pericle F, Kirken RA, Epling-Burnette PK, Blanchard DK, Djeu JY Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer 1996;66:367-73.
11. Noffz GT, Quin Z, Kopf M, Blankenstein T Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J Immunol 1998;160:345-50.
12. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-94.
13. Loeser S, Loser KBM, Rangachari M, et al. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 2007;204:879-91.
14. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
15. Pardoll D T cells and tumours. Nature 2001;411:1010-2.
16. Waldmann TA Immunotherapy: past, present and future. Nat Med 2003;9:269-77.
17. Porter DL The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999;50:369-86.
18. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
19. Kolb H-J Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83.
20. Jackaman C, Lew AM, Zhan Y, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008;20:1467-79.
21. Mauri C, Gray D, Mushtag N, Londei M Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
22. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50.
23. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994;179:1695-9.
24. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.